Emergent BioSolutions Inc.
Public company- Headquarters
- GAITHERSBURG, Maryland
- Ticker
- EBS
- CIK
- 0001367644
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
| Notice date | Workers affected | Cumulative |
|---|---|---|
| May 2, 2024 | 154 | 154 |
| May 16, 2024 | 86 | 240 |
| Aug 5, 2026 | 34 | 274 |
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFORichard Lindahl | Oct 16, 2026 | Departed |
| CFOFrank Vargo | Oct 16, 2026 | Appointed |
| CMOSimon Lowry | Aug 5, 2026 | Departed |
| Executive Vice President, Chief Growth OfficerStephanie Duatschek | Aug 5, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- MACROGENICS INC
Class II Director appointed: Michael Vasconcelles
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Merck & Co., Inc.
WARN notice: Rahway, NJ
- Executive departure
CFO departs: Richard Lindahl
Richard Lindahl, Chief Financial Officer of Emergent BioSolutions Inc., departs the role, effective December 31, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Chief Financial Officer
- Executive appointment
CFO appointed: Frank Vargo
Frank Vargo was named Interim Chief Financial Officer of Emergent BioSolutions Inc., effective January 1, 2027. Frank Vargo succeeds Richard Lindahl. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Interim Chief Financial Officer
- Executive departure
CMO departs: Simon Lowry
Simon Lowry, Chief Medical Officer, Head of Research and Development of Emergent BioSolutions Inc., departs the role, effective August 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: Chief Medical Officer, Head of Research and Development
- Executive appointment
Executive Vice President, Chief Growth Officer appointed: Stephanie Duatschek
Stephanie Duatschek was named Executive Vice President, Chief Growth Officer of Emergent BioSolutions Inc.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: Executive Vice President, Chief Growth Officer
Last verified Nov 8, 2026